Report Overview
Injectable implants are injections of material into the urethra to help control urine leakage (urinary incontinence) caused by a weak urinary sphincter.
Injectable therapy using bulking agents composed of synthetic materials, bovine collagen, or autologous substances augment the urethral wall and increase urethral resistance to urinary flow. The injection of bulking agents to treat a dysfunctional urethra is a minimally invasive method of correcting intrinsic sphincteric deficiency that results in stress urinary incontinence but is being performed less frequently in current practice.
Market Shares
The global Injectable Implant Urinary Incontinence Device market size was estimated at USD 112 million in 2024 and is projected to reach USD 177.17 million by 2032, exhibiting a CAGR of 5.90% during the forecast period.
North
America Injectable Implant Urinary Incontinence Device market size was estimated at USD 32.21 million in 2024, at a CAGR of 5.06% during the forecast period of 2025 through 2032.
Key Company
Market Segmentation (by Application)
• Hospitals and Clinics
• Ambulatory Surgery Centres
• Others
• Market Segmentation (by Type)
• Stress Incontinence
• Urge Incontinence
• Overflow Incontinence
• Functional Incontinence
Geographic Segmentation
• North America: USA, Canada, Mexico
• Europe: Germany, UK, France, Russia, Italy, Rest of Europe
• Asia-Pacific: China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific
• South America: Brazil, Argentina, Colombia, Rest of South America
• Middle East and Africa: Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA
https://www.statsmarketresearch.com/global-injectableimplant-urinary-incontinence-device-forecast-2025-203280-8035221
